Large B-cell lymphoma
Therapeutic area
Hematology
Rare disease
No
- Definition
- A B-cell lymphoma that is characterized by large lymphoid cells of the B-cell lineage that by definition form sheets or clusters.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Large B-cell lymphoma
- Alternative names
- large B-cell lymphoma
- Therapeutic area
- Hematology
- Severity
- Severe
- Hematology
- Immunology
- Oncology
- MONDO ID
- MONDO:0968974
- Parent condition
- MONDO:0004095
Related records
Broader conditions (16)
- B-cell neoplasm
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Human disease
- Immune system disorder
- Leukocyte disorder
- Lymphoid hemopathy
- Lymphoid neoplasm
- Lymphoma
- Neoplasm
- Neoplastic disease or syndrome
Trials (103)
- 89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)
- A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma
- A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
- A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
- A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
- A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma
- A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.
- A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
- A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
- A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T
- A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma
- Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
- AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL
- AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL
- An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
- An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
- Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies